WO1998010795B1 - Tumor homing molecules, conjugates derived therefrom, and methods of using same - Google Patents
Tumor homing molecules, conjugates derived therefrom, and methods of using sameInfo
- Publication number
- WO1998010795B1 WO1998010795B1 PCT/US1997/016086 US9716086W WO9810795B1 WO 1998010795 B1 WO1998010795 B1 WO 1998010795B1 US 9716086 W US9716086 W US 9716086W WO 9810795 B1 WO9810795 B1 WO 9810795B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor
- page
- new
- molecule
- seq
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 26
- 238000000034 method Methods 0.000 title claims abstract 7
- 210000005166 vasculature Anatomy 0.000 claims abstract 6
- 230000002491 angiogenic effect Effects 0.000 claims abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000004091 panning Methods 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Abstract
The present invention provides tumor homing molecules, which selectively home to a tumor. The invention also provides methods of using a tumor homing molecule to target an agent such as a drug to a selected tumor or to identify the target molecule expressed by the tumor. The invention also provides methods of targeting a tumor containing angiogenic vasculature by contacting the tumor with a molecule that specifically binds an αv-containing integrin. The invention further provides molecules that can selectively home to angiogenic vasculature. In addition, the invention provides a target molecule, which is specifically bound by a tumor homing molecule and is expressed by angiogenic vasculature. The invention also provides antibodies that bind to the target molecule and peptidomimetics that competitively inhibit binding of a ligand to the target molecule.
Claims
AMENDED CLAIMS
[received by the International Bureau on 15 May 1998 (15.05.98); original claim 35 amended; new claims 73-78 added; remaining claims unchanged (2 pages)]
35. A tumor homing peptide selected from the group consisting of CLSGSLSC (SEQ ID NO: 4) and CGSLVRC
(SEQ ID NO: 5) .
36. A tumor homing molecule identified by in vivo panning, comprising the steps of:
a) administering to a first subject having a tumor a library of diverse molecules;
b) collecting a sample of the tumor;
c) identifying a molecule that homes to said tumor;
d) collecting a sample of normal tissue corresponding to said tumor; and
e) determining that said molecule that homes to said tumor is not present in said normal tissue, thereby identifying said molecule as a tumor homing molecule,
provided said molecule is not an antibody.
37. A method of directing a moiety to a tumor, comprising contacting the tumor with the conjugate of claim 1.
38. The method of claim 37, wherein said contacting step is performed in vi tro .
39. The method of claim 37, wherein said contacting step is performed in vivo.
72. The method of claim 69, wherein said molecule is CDCRGDCFC (SEQ ID NO: 14) .
73. A tumor homing peptide selected from the group consisting of CNGRC (SEQ ID NO : 8) and
CNGRCVSGCAGRC (SEQ ID NO: 3) .
74. The conjugate of claim 1, wherein said moiety induces apoptosis in a cell.
75. A tumor homing peptide, comprising the amino acid sequence GSL.
76. A target molecule, which is expressed in tumor vasculature, wherein said target molecule binds a tumor homing peptide comprising the amino acid sequence GSL.
77. A target molecule, which is expressed in angiogenic vasculature, wherein said target molecule binds a tumor homing peptide comprising the amino acid sequence GSL.
78. A target molecule, which is expressed in angiogenic vasculature, wherein said target molecule binds a tumor homing peptide comprising the amino acid sequence NGR.
STATEMENT UNDER ARTICLE 19
Upon entry of the amendments, claims 1 to 78 will be pending. The amendments shown above and included on the Substitute pages are supported for the following reasons.
The specification has been amended at page 34, lines 9-10, to correctly indicate that the size of a phage is 900-1000 nm. Support for the amendment is provided, in part, by the language at page 34, as well as by knowledge in the art regarding the size of M13 bacteriophage, which harbor the fuse 5 vector (-see page 70, lines 11-13; and Exhibit A, Pasqualini et al . , Nature Biotechnol. 15:542 (1997), at page 545, right column second paragraph, indicating phage are 900 nm in length) . Thus, the amendment merely corrects an omission in not deleting a question posed prior to filing the specification and is supported, in part, by the specification and by knowledge in the art and, therefore, does not add new matter. Entry of Substitute page 34, containing the amended language, therefore, respectfully is requested.
Claim 35 has been amended to cancel recitation of the peptide of SEQ ID NO: 3, which has been added to new claim 73, and to insert therefor the peptide of SEQ ID NO: 4, which is supported in Table 2 (page 80, line 14) . The amendment is made to include only peptides sharing a "GSL" motif in claim 35 and, similarly, to include only peptides having a "CNGRC" motif in new claim 73. Thus, new claim 73 recites the peptide of SEQ ID NO: 3 and the peptide, CNGRC (SEQ ID NO: 8) . New claim 73, including the CNGRC peptide, is supported, for example, at page 38, line 35, to page 39, line 2, which indicates that CNGRC is a tumor homing peptide. Thus, the amendment to claim 35 and new claim 73 are supported
by the specification and the claims as filed and do not add new matter.
New claim 74 also has been added. New claim 74 is supported, for example, at page 45, lines 14-19, and, therefore, does not add new matter. New claim 75 is supported, for example, at page 4, lines 13-19; at page 38, lines 6-33; and at page 40, lines 27-35, which indicate that "GSL" containing peptides are considered within the claimed invention, and, therefore, the new claims do not add new matter .
New claims 76 to 78 are based, in part, on originally filed claim 52 and are supported, for example, at page 67, line 34, to page 68, line 17, and, for example, at page 4, lines 13-19, and page 5, lines 13-16. Thus, new claims 76 to 78 do not add new matter.
For the above reasons, it is submitted that the amendments to the claims and the new claims do not add new matter. Accordingly, entry of Substitute pages 95 and 100, containing the amended claim 35 and new claims 73 to 78, respectfully is requested.
Entry of Substitute pages--35, 95 and 100 respectfully is requested. The Examiner is invited to contact the undersigned attorney or Cathryn Campbell if there are any questions relating to the subject application.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44122/97A AU4412297A (en) | 1996-09-10 | 1997-09-10 | Tumor homing molecules, conjugates derived therefrom, and methods of using sa me |
CA002265484A CA2265484C (en) | 1996-09-10 | 1997-09-10 | Tumor homing molecules, conjugates derived therefrom, and methods of using same |
EP97942422A EP0927045B1 (en) | 1996-09-10 | 1997-09-10 | Tumor homing molecules, conjugates derived therefrom, and methods of using same |
JP10513856A JP2001501600A (en) | 1996-09-10 | 1997-09-10 | Tumor homing molecules, conjugates derived therefrom, and methods of using the same |
DE69734887T DE69734887T2 (en) | 1996-09-10 | 1997-09-10 | TUMOR FINDING MOLECULES, DIVIDING CONJUGATES, AND METHOD FOR USE THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71006796A | 1996-09-10 | 1996-09-10 | |
US08/710,067 | 1996-09-10 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO1998010795A2 WO1998010795A2 (en) | 1998-03-19 |
WO1998010795A3 WO1998010795A3 (en) | 1998-05-22 |
WO1998010795B1 true WO1998010795B1 (en) | 1998-07-16 |
WO1998010795A9 WO1998010795A9 (en) | 2001-06-21 |
Family
ID=24852493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/016086 WO1998010795A2 (en) | 1996-09-10 | 1997-09-10 | Tumor homing molecules, conjugates derived therefrom, and methods of using same |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0927045B1 (en) |
JP (1) | JP2001501600A (en) |
AU (1) | AU4412297A (en) |
CA (1) | CA2265484C (en) |
DE (1) | DE69734887T2 (en) |
WO (1) | WO1998010795A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7186810B2 (en) | 1998-10-23 | 2007-03-06 | Amgen Inc. | Modified peptides as therapeutic agents |
US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
US9114175B2 (en) | 2005-08-12 | 2015-08-25 | Amgen Inc. | Modified Fc molecules |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001516055A (en) * | 1997-09-10 | 2001-09-25 | ザ バーナム インスティチュート | Methods for identifying molecules that home to the angiogenic vasculature in tumors |
US6180084B1 (en) | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
EP1062232B1 (en) | 1998-03-13 | 2008-09-10 | The Burnham Institute | Molecules that home to various selected organs or tissues |
US6174687B1 (en) | 1999-02-26 | 2001-01-16 | The Burnham Institute | Methods of identifying lung homing molecules using membrane dipeptidase |
US6852318B1 (en) | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
CA2238257A1 (en) * | 1998-05-22 | 1999-11-22 | Universite De Montreal | Endocytosis of amf-r and uses thereof in cancer therapy |
DE19845798A1 (en) * | 1998-09-29 | 2000-04-13 | Schering Ag | Use of neoangiogenesis markers for diagnosis and therapy of tumors, agents containing them, and methods for their production |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
ES2388341T3 (en) | 1998-10-23 | 2012-10-11 | Kirin-Amgen Inc. | Dimeric thrombopoietin mimetic peptides that bind to the MPL receptor and that have thrombopoietic activity |
CA2359633A1 (en) * | 1999-01-22 | 2000-07-27 | The Burnham Institute | Homing pro-apoptotic conjugates and methods of using same |
US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
US7049140B1 (en) | 1999-04-29 | 2006-05-23 | Vanderbilt University | X-ray guided drug delivery |
WO2001009611A2 (en) * | 1999-07-29 | 2001-02-08 | University Of Vermont And State Agricultural College | An vivo identification of specific binding molecules for cancer detection |
JP2003520808A (en) * | 2000-01-21 | 2003-07-08 | ザ バーナム インスティチュート | Chimeric prostate homing peptide with pro-apoptotic activity |
US7109303B2 (en) | 2000-02-15 | 2006-09-19 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
US7309694B2 (en) | 2000-02-15 | 2007-12-18 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
IT1317835B1 (en) | 2000-02-15 | 2003-07-15 | San Raffaele Centro Fond | MODIFIED CYTOKINES FOR USE IN CANCER THERAPY. |
JP2003526683A (en) | 2000-03-15 | 2003-09-09 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Peptidase-cleavable targeted antineoplastic drugs and their therapeutic use |
DE60111733T2 (en) | 2000-04-12 | 2006-05-18 | Amersham Health As | INTEGRIN BINDING PEPTIDE DERIVATIVES |
US7220824B1 (en) | 2000-08-28 | 2007-05-22 | Bayer Aktiengesellschaft | Integrin-mediated drug targeting |
US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
NO20004795D0 (en) | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptide-based compounds |
EP1238678A1 (en) | 2001-03-08 | 2002-09-11 | Bayer Aktiengesellschaft | Enzyme-activated cytostatic conjugates with integrin ligands |
US7666391B2 (en) | 2001-06-01 | 2010-02-23 | Burnham Institute For Medical Research | Breast homing peptides and methods of identifying same using aminopeptidase P |
IL159310A0 (en) | 2001-07-10 | 2004-06-01 | Amersham Health As | Peptide-based compounds |
US7306925B2 (en) | 2001-11-09 | 2007-12-11 | Vanderbilt University | Phage antibodies to radiation-inducible neoantigens |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
US7192921B2 (en) | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
DE60230822D1 (en) * | 2001-11-08 | 2009-02-26 | Burnham Inst | PEPTIDES WITH HOMING FOR LYMPHOTIC TARTOR AND ITS USE |
CA2467836A1 (en) | 2001-11-20 | 2003-09-04 | Duke University | Interfacial biomaterials |
CA2476556A1 (en) | 2002-02-13 | 2003-08-21 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
EP1346729A1 (en) * | 2002-03-19 | 2003-09-24 | Cardiovascular Research Institute Maastricht | Targeting of myocardial angiogenesis through CD13/APN |
GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
WO2004015392A2 (en) * | 2002-08-08 | 2004-02-19 | Targeted Molecules Corporation | Improved method to identify targeting molecules |
US7488792B2 (en) | 2002-08-28 | 2009-02-10 | Burnham Institute For Medical Research | Collagen-binding molecules that selectively home to tumor vasculature and methods of using same |
US7393653B2 (en) | 2002-09-06 | 2008-07-01 | The Burnham Institute | Methods of modulating cell death based on the Bit1/AES regulatory pathway |
MXPA05005469A (en) * | 2002-11-25 | 2005-09-08 | Attenuon Llc | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof. |
US20050009740A1 (en) * | 2003-03-31 | 2005-01-13 | Greenville Hospital System | Anti-tumor vasculature effects of human serum albumin derivatives |
GB0312309D0 (en) | 2003-05-29 | 2003-07-02 | Gaslini Children S Hospital G | Targeted liposome |
US7122353B2 (en) | 2003-08-05 | 2006-10-17 | Wisconsin Alumni Research Foundation | Targeted carrier fusions for delivery of chemotherapeutic agents |
US7598341B2 (en) | 2003-10-31 | 2009-10-06 | Burnham Institue For Medical Research | Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs |
MX2007000216A (en) | 2004-07-08 | 2007-03-15 | Amgen Inc | Therapeutic peptides. |
CN101052408B (en) * | 2004-09-07 | 2013-03-27 | 伯纳姆研究院 | Peptides that selectively home to heart vasculature and related conjugates and methods |
EP1831254B1 (en) | 2004-12-23 | 2012-06-06 | Molmed SpA | Conjugation product |
ITMI20050328A1 (en) | 2005-03-03 | 2006-09-04 | Univ Degli Studi Milano | PEPTIDOMIMETRIC COMPOUNDS AND PREPARATION OF BIOLOGICALLY ACTIVE DERIVATIVES |
NZ569818A (en) | 2005-12-16 | 2012-07-27 | Catherine M Shachaf | Diagnostic system for the detection and diagnosis of skin cancer |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
US9957293B2 (en) | 2006-08-23 | 2018-05-01 | Yeda Research And Development Company Ltd. | Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses |
WO2008136869A2 (en) * | 2006-12-06 | 2008-11-13 | Burnham Institute For Medical Research | Methods and compositions related to targeting wounds, regenerating tissue, and tumors |
FI20075483A0 (en) * | 2007-06-25 | 2007-06-25 | Licentia Oy | New peptide |
MX2010009530A (en) * | 2008-02-27 | 2010-11-30 | Yeda Res & Dev | Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors. |
BRPI0920108A2 (en) * | 2008-10-23 | 2016-12-13 | Steba Biotech N V | cyclic peptidomimetic containing argin, glycine, aspartic acid (rgd), cyclic peptidomimetic conjugate containing rgd, pharmaceutical composition, conjugate and use thereof. |
CN102265158A (en) | 2008-12-23 | 2011-11-30 | 通用电气健康护理有限公司 | Application of 99mtc peptide-based compound as a bone marrow imaging agent |
FR2968662B1 (en) | 2010-12-10 | 2013-11-22 | Roussy Inst Gustave | NOVEL PRE-ACTIVE OXAZAPHOSPHORINE DERIVATIVES, USE AND METHOD OF PREPARATION |
WO2013019730A1 (en) | 2011-07-29 | 2013-02-07 | The Washington University | Antibodies to tip-1 and grp78 |
CA2919088A1 (en) * | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
EP3172222A4 (en) | 2014-07-24 | 2018-03-21 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
CN106518965A (en) * | 2015-09-10 | 2017-03-22 | 华东理工大学 | Polypeptide probe for specific identification of lysophosphatidic acid, preparation and applications thereof |
WO2018148595A1 (en) | 2017-02-10 | 2018-08-16 | Washington University | Antibodies to tip1 and methods of use thereof |
IL282748B1 (en) | 2018-11-05 | 2025-03-01 | Bayer Pharma AG | Cytostatic conjugates with integrin ligands |
WO2023057813A1 (en) | 2021-10-04 | 2023-04-13 | Vincerx Pharma Gmbh | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders |
EP4412655A1 (en) | 2021-10-04 | 2024-08-14 | Vincerx Pharma GmbH | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder |
CN118354796A (en) | 2021-10-04 | 2024-07-16 | 文赛克斯制药有限责任公司 | Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5845594A (en) * | 1992-11-13 | 1994-06-08 | Scripps Research Institute, The | Cancerous b cell treatment using substituted nucleoside derivatives |
US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
EP0987275B1 (en) * | 1995-09-11 | 2008-01-02 | La Jolla Cancer Research Foundation | Molecules that home to a selected organ or tissue in vivo |
-
1997
- 1997-09-10 CA CA002265484A patent/CA2265484C/en not_active Expired - Lifetime
- 1997-09-10 AU AU44122/97A patent/AU4412297A/en not_active Abandoned
- 1997-09-10 DE DE69734887T patent/DE69734887T2/en not_active Expired - Lifetime
- 1997-09-10 EP EP97942422A patent/EP0927045B1/en not_active Expired - Lifetime
- 1997-09-10 WO PCT/US1997/016086 patent/WO1998010795A2/en active IP Right Grant
- 1997-09-10 JP JP10513856A patent/JP2001501600A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7186810B2 (en) | 1998-10-23 | 2007-03-06 | Amgen Inc. | Modified peptides as therapeutic agents |
US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
US9114175B2 (en) | 2005-08-12 | 2015-08-25 | Amgen Inc. | Modified Fc molecules |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998010795B1 (en) | Tumor homing molecules, conjugates derived therefrom, and methods of using same | |
DE69629127T2 (en) | DISCONNECTING MEDIUM FOR IgG AND PROTEIN A VARIANT | |
JP7417432B2 (en) | New linker, its production method and its application | |
CA2265484A1 (en) | Tumor homing molecules, conjugates derived therefrom, and methods of using same | |
JP4229704B2 (en) | Fc region polypeptide binding molecule | |
Fourie et al. | Common and divergent peptide binding specificities of hsp70 molecular chaperones. | |
DE69526665T2 (en) | ANTI-BINDING PEPTIDES (ABTIDES) FROM PEPTIDE LIBRARIES | |
CA2204535A1 (en) | Molecules that home to a selected organ or tissue in vivo and methods of identifying same | |
JPS62500100A (en) | Acid-cleavable compounds | |
WO2003046560B1 (en) | Self-assembly molecules | |
CA2583009A1 (en) | Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography | |
DE69731626D1 (en) | SH3-BINDING PEPTIDES OF CORTACTIN AND THEIR USE | |
JP2006521819A (en) | Intracellular transport of small molecules, proteins, and nucleic acids | |
DE69938054D1 (en) | ANTIBODY VARIANTS HAVING HIGHER BINDING SAFFINITIES COMPARED TO PARENTAL ANTIBODIES | |
White et al. | Preparation of site-specific antibodies to acetylated histones | |
CA2305597A1 (en) | Affinity markers for human serum albumin | |
Oblas et al. | Analysis of receptor-ligand interactions using nitrocellulose gel transfer: application to Torpedo acetylcholine receptor and alpha-bungarotoxin | |
CA2193323C (en) | Process for preparing a synthetic calibrator for use in sandwich immunoassays, which calibrator consists of an antibody against one of the antibodies used in the assay and of a sequence of the analyte | |
Benditt et al. | Interaction of a nuclear location signal with isolated nuclear envelopes and identification of signal-binding proteins by photoaffinity labeling. | |
EP0650053B1 (en) | Synthetic standard for immunoassays | |
Davis et al. | Diversity in membrane binding sites of ankyrins: brain ankyrin, erythrocyte ankyrin, and processed erythrocyte ankyrin associate with distinct sites in kidney microsomes | |
ATE542138T1 (en) | HER-2 BINDING ANTAGONISTS | |
Morrison et al. | Determination of the structural domain of ApoAI recognized by high density lipoprotein receptors. | |
WO1990006323A3 (en) | Chimeric proteins incorporating a metal binding protein | |
Yoshiya et al. | Development of trityl group anchored solubilizing tags for peptide and protein synthesis |